C-MYC ONCOGENE AMPLIFICATION AND CYTOMETRIC DNA-PLOIDY PATTERN AS PROGNOSTIC FACTORS IN MUSCULOSKELETAL NEOPLASMS

被引:17
作者
BARRIOS, C
CASTRESANA, JS
FALKMER, UG
ROSENDAHL, I
KREICBERGS, A
机构
[1] KAROLINSKA HOSP & INST,DEPT ORTHOPED,STOCKHOLM,SWEDEN
[2] KAROLINSKA HOSP & INST,DEPT PATHOL & ONCOL,STOCKHOLM,SWEDEN
[3] KAROLINSKA HOSP & INST,CTR ONCOL,STOCKHOLM,SWEDEN
关键词
D O I
10.1002/ijc.2910580605
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between c-myc oncogene amplification in neoplastic cells as determined by means of Southern-blot analysis, and their nuclear DNA content as assessed by combined flow and image cytometry, was investigated in fresh tumor specimens from 33 patients with musculoskeletal neoplasms. Amplification, without rearrangement of the c-myc proto-oncogene, was detected in 4 out of 7 bone sarcomas and in 6 out of 26 soft-tissue sarcomas, but in none of 3 benign giant-cell bone tumors. Among the 10 cases with c-myc amplification, 2 were found to be cytometrically DNA diploid, 2 DNA tetraploid, and 6 DNA aneuploid. Conversely, there were 10 tumors displaying extremely aneuploid DNA patterns without c-myc oncogene amplification. Thus, there was no relationship between c-myc amplification and DNA ploidy; neither did the percentage of S-phase cells, as determined by means of image cytometry, correlate significantly with the occurrence of c-myc amplification. A surprising sex-bias was observed; all 6 cases of c-myc-amplified soft-tissue sarcomas occurred in females, whereas none of the 11 males with such sarcomas showed this amplification. When the clinical follow-up data of the patients were scrutinized, it was found that the DNA ploidy pattern of the neoplastic cell nuclei, in combination with the S-phase values, as well as the occurrence of c-myc amplification, yielded prognostic information, being statistically significant 2 years after the diagnosis. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:781 / 786
页数:6
相关论文
共 24 条
[1]  
ARMITAGE P, 1987, STAT METHODS MED RES, P125
[2]  
BARRIOS C, 1994, ONCOLOGY, V51, P13
[3]   AMPLIFICATION OF C-MYC ONCOGENE AND ABSENCE OF C-HA-RAS POINT MUTATION IN HUMAN BONE SARCOMA [J].
BARRIOS, C ;
CASTRESANA, JS ;
RUIZ, J ;
KREICBERGS, A .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1993, 11 (04) :556-563
[4]  
BAUER HCF, 1988, CANCER, V61, P1430, DOI 10.1002/1097-0142(19880401)61:7<1430::AID-CNCR2820610725>3.0.CO
[5]  
2-M
[6]   THE MOLECULAR-GENETICS OF CANCER [J].
BISHOP, JM .
SCIENCE, 1987, 235 (4786) :305-311
[7]   AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE [J].
BRODEUR, GM ;
SEEGER, RC ;
SCHWAB, M ;
VARMUS, HE ;
BISHOP, JM .
SCIENCE, 1984, 224 (4653) :1121-1124
[8]   THE MYC ONCOGENE - ITS ROLE IN TRANSFORMATION AND DIFFERENTIATION [J].
COLE, MD .
ANNUAL REVIEW OF GENETICS, 1986, 20 :361-384
[9]  
ENZINGER FM, 1988, SOFT TISSUE TUM0RS
[10]   METHODOLOGICAL ASPECTS ON FLOW AND IMAGE CYTOMETRIC NUCLEAR-DNA ASSESSMENTS IN PROSTATIC ADENOCARCINOMA [J].
FALKMER, UG .
ACTA ONCOLOGICA, 1991, 30 (02) :201-203